| 1708.1 - Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV |
| 1657.1 - Rhenium-188 brachytherapy for non-melanoma skin cancer |
| 1791 – Dinutuximab beta for primary relapse and refractory high-risk neuroblastoma |
| 1789 – Computed tomography (CT) colonography for the detection of colorectal polyps and colorectal cancer |
| 1788 – ArteraAI Prostate Biopsy Assay for patients with localised prostate cancer |
| 1787 – Immunohistochemistry testing of solid tumour tissue to determine folate receptor alpha (FRɑ) expression status in adults with platinum-resistant ovarian cancer, to determine eligibility for treatment with PBS subsidised mirvetuximab soravtansine |
| 1786 – FreeStyle Libre 2 continuous glucose monitoring system for people with insulin dependent type 2 diabetes, gestational diabetes and type 3c diabetes |
| 1785 - Dexcom ONE continuous glucose monitoring system for people with insulin dependent type 2 diabetes |
| 1783 – Genetic testing to detect PIK3CA mutations in patients with hormone receptor (HR)-positive, HER-2 negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised inavolisib |
| 1782 – Genetic testing to detect estrogen receptor 1 (ESR1) variants in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant |
| 1779 – Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib |
| 1781 – Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test |
| 1778 – Fibroblast growth factor 23 (FGF-23) testing for patients with a high pre-test probability of X-linked hypophosphatemia (XLH) to determine eligibility for burosumab on the Pharmaceutical Benefits Scheme (PBS) |
| 1777 – Review of MBS items for clinically indicated gross and histologic examination of placentas in perinatal deaths |
| 1732.1 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates |
| 1738 – Two testing options to detect early-stage Alzheimer's Disease, to determine eligibility for PBS subsidised lecanemab treatment |
| 1776 – Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II; Hunter syndrome) |
| 1774 – Newborn bloodspot screening for glycogen storage disease, Type II (GSD II; Pompe disease) |
| 1775 – Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I) |
| 1773 – Autologous chondrocyte implantation for symptomatic articular cartilage defects greater than 2cm2 of the knee |
| 1771 – Axicabtagene ciloleucel therapy for patients with relapsed or refractory follicular lymphoma |
| 1769 – Human leukocyte antigen (HLA) testing for hypersensitivity to carbamazepine and oxcarbazepine |
| 1772 – Single chamber leadless pacing with atrio-ventricular synchronous pacing in patients with bradycardia |
| 1770 – Valve-in-valve transcatheter aortic valve implantation for patients with symptomatic structural valve deterioration resulting in aortic stenosis, insufficiency/regurgitation or both |
| 1751 – Valoctocogene roxaparvovec gene therapy for congenital haemophilia A |
| 1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment |
| 1507.1 – Germline BRCA mutation testing in patients with locally advanced or metastatic HER2-negative breast cancer to determine eligibility for PBS-listed olaparib treatment |
| 1766 – Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment |
| 1765 – Amendment of MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration-resistant prostate cancer) to include talazoparib |
| 1627.1 – Point-of-care testing for sexually transmitted infections provided by Aboriginal Medical Services or Aboriginal Community Controlled Heath Services in rural or remote areas |
| 1737.1 – Newborn bloodspot screening for Sickle Cell Disease |
| 1722.1 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma |
| 1720 - 68Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy |
| 1764 - Micro-bypass glaucoma surgery device implantation into the suprachoroidal space as a standalone procedure in patients with open angle glaucoma |
| 1662.2 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques |
| 1523.1- Transluminal insertion, management and removal of an intravascular microaxial blood pump (Impella®), for patients requiring mechanical circulatory support |
| 1754 - Surgical Procedures for Gender Affirmation in Adults with Gender Incongruence |
| 1763 – Amendment of MBS Item 11512 to include the use of portable home spirometry via telehealth |
| 1743 - Optical coherence tomography (OCT) guided coronary stent insertion for patients eligible for coronary revascularisation |
| 1761 - Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease |
| 1760 - DPYD genotyping to predict fluoropyrimidine-induced toxicity |
| 1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease |
| 1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density testing to include patients aged 60-69 years |
| 1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma |
| 1723.1 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia |
| 1750 - Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmaceutical Benefits Scheme |
| 1593.1 – Bioinductive implant for the repair of rotator cuff tear |
| 1749 – Insertion of durable left ventricular assist device for use as destination therapy |
| 1748 – Review of Tisagenlecleucel for treatment of confirmed relapsed/refractory CD19-positive acute lymphoblastic leukaemia in children and young adults up to 25 years old |
| 1747 – Permanent Medicare Benefits Schedule (MBS) items for COVID-19 nucleic acid testing |
| 1686.1 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer |
| 1689.1 – Quantification of NT-proBNP in patients with diagnosed pulmonary arterial hypertension for ongoing risk assessment |
| 1752 – Anal human papillomavirus (HPV) and cytology testing in high-risk populations to determine access to high-resolution anoscopy and ablative treatment to prevent anal cancer |
| 1741 – Continuous nerve blockade using a catheter technique |
| 1740 – N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) to aid in the diagnosis of patients with suspected heart failure in a non-hospital setting |
| 1739 – Percutaneous electrical nerve stimulation therapy for chronic neuropathic pain |
| 1728 – Etranacogene dezaparvovec for the treatment of Haemophilia B |
| 1744 – 177Lutetium(nca)-DOTA-octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours |
| 1549 – PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer |
| 1658.1 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib |
| 1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib |
| 1724 – Cardiac technical support services provided by industry employed technicians |
| 1737 – Newborn bloodspot screening for Sickle Cell Disease and Beta Thalassaemia |
| 1736 – Lipoprotein(a) testing as an independent predictor of cardiovascular disease |
| 1727 – Deep brain stimulation for treatment-refractory obsessive compulsive disorder |
| 1732 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates |
| 1725 – Transanal total mesorectal excision for the treatment of rectal cancer and benign disease |
| 1718 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment |
| 1677.1 – Pharmacy Diabetes Screening Trial |
| 1723 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia |
| 1525.1 – Low dose rate brachytherapy for intermediate and high-risk prostate cancer |
| 1662.1 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques |
| 1722 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma |
| 1719 – Insertion of a bioabsorbable implant for nasal airway obstruction due to lateral wall insufficiency |
| 1710 – Newborn bloodspot screening for X-linked adrenoleukodystrophy |
| 1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment |
| 1714 – National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A |
| 1717 – Extravascular implantable cardioverter defibrillator therapy for patients at risk of ventricular arrhythmia |
| 1721 – Small gene panel testing for non-small cell lung carcinoma |
| 1713 – Cardiac MRI in the diagnosis of myocarditis |
| 1712 – Out-of-laboratory sleep studies in the diagnosis and management of sleep disordered breathing in children & adolescents |
| 1408.1 – A prognostic RT-qPCR test for prediction of risk of distant recurrence of breast cancer under endocrine treatment |
| 1709 – Somatic gene testing for the diagnosis of glioma, including glioblastoma |
| 1711 – Review of MBS items for subacromial decompression |
| 1706 – Angiogenic and anti-angiogenic markers for identification and management of preeclampsia |
| 1705 – Structured prenatal risk assessment for preterm preeclampsia |
| 1701 – Deep brain stimulation of the thalamus for the treatment of severe refractory epilepsy |
| 1700 – Totally thoracoscopic exclusion of the left atrial appendage for patients with non-valvular atrial fibrillation |
| 1708 – Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV |
| 1702 – Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours |
| 1703 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia |
| 1707 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia |
| 1695 – Procedures for the implantation and refill-exchange of the Port Delivery System with ranibizumab to treat neovascular age-related macular degeneration |
| 1678 – Integrating Pharmacists within Aboriginal Community Controlled Health Services to Improve Chronic Disease Management (IPAC Project) |
| 1698 – Chronic Pain MedsCheck Trial |
| 1699 – National Lung Cancer Screening Program |
| 1679 – Improved medication management for Aboriginal and Torres Strait Islanders Feasibility Study (IMeRSe Feasibility Study) |
| 1614.1 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor |
| 1686 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer |
| 1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma |
| 1684 – Genetic testing for variants associated with haematological malignancies |
| 1675 – Whole Genome Sequencing for the diagnosis of mitochondrial disease |
| 1683 – MRI of the liver, for the evaluation of hepatic metastases for initial staging or restaging prior to treatment using interventional techniques |
| 1682 – Amendment to MBS Item 63464 – MRI for the detection of breast cancer in asymptomatic high-risk patients |
| 1685 – Ventral rectopexy for the treatment of rectal prolapse and intussusception |
| 1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease |
| 1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension |
| 1697 – Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia |
| 1680 – Genetic testing for childhood hearing impairment |
| 1665 – Radiofrequency echographic multi spectrometry for bone density measurement and determination of osteopenia/osteoporosis |
| 1555.1 – Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first line (lifestyle modification) and second line (pharmacotherapy) treatments |
| 1677 – Pharmacy Diabetes Screening Trial |
| 1602.1 – Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib |
| 1522.1 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma |
| 1676 – Amendments to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma – amend clinical criteria for patients with Transformed Follicular Lymphoma (TFL) and propose inclusion of patients with grade 3B follicular lymphoma (3B FL) |
| 1637 – Expanded Reproductive Carrier Screening of couples for joint carrier status of genes associated with autosomal recessive and X-linked conditions |
| 1674 – Testing for mismatch repair deficiency (dMMR) in endometrial cancer to help determine eligibility for PBS-subsidised dostarlimab |
| 1627 – Point-of-care testing for sexually transmitted infections provided by Aboriginal Medical Services or Aboriginal Community Controlled Heath Services in rural or remote areas |
| 1672 – Procedures for the insertion or removal of a leadless permanent pacemaker for the treatment of bradyarrhythmia |
| 1595.1 – Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure therapy |
| 1671 – Targeted carrier testing for severe monogenic conditions |
| 1669 – KRAS G12C variant testing to determine eligibility for PBS-subsidised sotorasib second-line therapy in patients with locally advanced or metastatic non small cell lung cancer |
| 1666 – Exclusion of the left atrial appendage via surgical epicardial clip implantation concomitant to open cardiac surgery for patients with atrial fibrillation |
| 1668 – Whole body magnetic resonance imaging for detection of cancer in individuals with germline pathogenic TP53 variants |
| 1673 – Single operator, single use, peroral cholangiopancreatoscopy for diagnosis of indeterminate biliary strictures and removal of difficult biliary stones |
| 1546.1-Abdominoplasty with repair of rectus diastasis (also known as rectus divarication) following pregnancy |
| 1640 - Transcatheter Aortic Valve Implantation (TAVI) via transfemoral delivery for patients at low risk for surgery |
| 1354.1 – Intravascular ultrasound guided coronary stent insertion |
| 1646 – Whole genome sequencing of antimicrobial-resistant pathogens |
| 1662 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques |
| 1661 – Implantation of minimally invasive interspinous decompression spacers for moderate degenerative lumbar spinal stenosis |
| 1657 – Rhenium-188 brachytherapy for non-melanoma skin cancer |
| 1658 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib |
| 1660 - Diagnostic testing for mesenchymal-epithelial transition Exon 14 skipping alterations in non-small cell lung cancer, to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment |
| 1659 – Catheter-based renal denervation for uncontrolled elevated systolic blood pressure |
| 1656 – Vertebral body tethering for adolescent idiopathic scoliosis |
| 1664 - Improvements to the National Cervical Screening Program Self-Collection Policy |
| 1663 – Review of Continuous Glucose Monitoring (CGM) products provided through the CGM Initiative |
| 1642 – Programmed Death Ligand 1 testing for access to cemiplimab for the treatment of locally advanced or metastatic non-small cell lung cancer |
| 1652 – Transcatheter aortic valve implantation via transfemoral delivery for patients at intermediate risk for surgery |
| 1647– Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma |
| 1374.1 – Subcutaneous implantable cardioverter defibrillator therapy for the prevention of sudden cardiac death |
| 1653 – Amendment to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma - removal of the requirement for patients to be “CD19-positive” |
| 1649 – Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter |
| 1643 - Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer Disease |
| 1648 - OncoSil™ for locally advanced unresectable pancreatic cancer |
| 1634 – Comprehensive genomic profiling of non-small cell lung cancer tumour tissue specimens using next generation sequencing assays |
| 1651 – Integrated, closed-system, extracorporeal photopheresis systems for the treatment of chronic graft-versus-host disease |
| 1195.1 - F-18 flurodeoxyglucose positron emission tomography (FDG PET) for the diagnosis of Alzheimer Disease |
| 1631 - Home sleep apnoea test utilizing peripheral arterial tone |
| 1635 - Transcatheter aortic valve implantation via transfemoral delivery using the balloon-expandable valve system for patients at low risk for surgery |
| 1630 - Hypoglossal nerve stimulation using the Genio System for the treatment of moderate to severe obstructive sleep apnoea (OSA) in patients who have failed or are intolerant to continuous positive airway pressure (CPAP) |
| 1624 - 17p deletion testing for access to acalabrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
| 1610 - Clostridium botulinum type A toxin-haemagglutin complex (Dysport) for the treatment of moderate to severe upper-limb spasticity due to cerebral palsy |
| 1629 – Defensive Antibacterial Coating (DAC) 5ml Kit |
| 1582 - Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of Neuromyelitis optica (NMO) |
| 1632 – PSMA PET/CT imaging for informing treatment of patients with prostate cancer |
| 1638 – Proton beam therapy for paediatric and rare cancers |
| 1628 – Alpha-1-Antitrypsin Genotyping |
| 1612 - Prostatic urethral lift procedure for men with benign prostatic hyperplasia |
| 1625 – Dinutuximab beta for high-risk neuroblastoma |
| 1586 - Transurethral water vapour ablation for the treatment of benign prostatic hyperplasia |
| 1622 - Cardiac ablation devices for use in ventricular arrhythmia and supraventricular tachycardia |
| 1623 – Voretigene neparvovec (Luxturna) for the treatment of biallelic RPE-65-mediated Inherited Retinal Dystrophies |
| 1626 – Mentor Textured breast implants and expanders compared with smooth breast implants and expanders on the Prostheses List |
| 1618 – Testing of tumour prostate tissue to detect BRCA1/2 pathogenic gene variants in men with metastatic castration-resistant prostate cancer to help determine eligibility for PBS olaparib |
| 1620 – Magnetic Resonance Image Guided Radiation Therapy |
| 1619 – Testing of blood to detect pathogenic germline BRCA1 or BRCA2 gene variants, in patients with metastatic pancreatic cancer to help determine eligibility for PBS olaparib |
| 1607 – 17p deletion testing for access to acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia |
| 1621 - Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme |
| 1617 - BRAF V600 testing to help determine eligibility for PBS access to Braftovi (encorafenib), in patients with metastatic colorectal cancer (Stage IV) |
| 1615 – Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation |
| 1613 – Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity |
| 1614 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor |
| 1485.1 - Sentinel Lymph Node Biopsy for intermediate thickness melanoma |
| 1344.2 - Assessment of foot and ankle services by podiatric surgeons (Resubmission) |
| 1420.1 - Extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma |
| 1608 - Amnion membrane (human tissue) for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs |
| 1568 - Germline BRCA mutation testing to determine eligibility for talazoparib treatment in patients with locally advanced or metastatic HER2-negative breast cancer (either hormone receptor positive or triple negative) |
| 1606 – Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib |
| 1584 – Radionuclide Imaging for for the diagnosis of transthyretin amyloid cardiomyopathy |
| 1196.3 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (Resubmission) |
| 1602 - Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib |
| 1605 - Transcatheter delivery of a dual-filter cerebral embolic protection system during transcatheter aortic valve implantation |
| 1604 - PIK3CA mutation testing for postmenopausal women or men with advanced breast cancer who have progressed during or following treatment with an aromatase inhibitor |
| 1603 - Transcatheter aortic valve implantation (TAVI) via transfemoral delivery, using the SAPIEN 3 balloon-expandable valve (BEV) system, for patients at intermediate risk for surgery |
| Sixth Community Pharmacy Agreement (6CPA) Medication Management Review (MMR) Programs |
| 1599 - Genomic testing for the diagnosis of heritable cardiomyopathies |
| 1600 - Genetic testing for heritable kidney disease (other than Alport syndrome) |
| 1598 - Genetic testing for diagnosis of inheritable cardiac rhythm disorders |
| 1595 - Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure (CPAP) therapy |
| 1597 - Cryoablation for biopsy-confirmed renal cell carcinoma (RCC) ≤4cm in patients not suitable for partial nephrectomy |
| 1596 - Coronary artery bypass graft surgery with one or more saphenous vein grafts, supported and reinforced by an external mesh support |
| 1585 - Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders |
| 1429.1 - Targeted intraoperative radiotherapy for early-stage breast cancer |
| 1353.1 - Measurement of Calprotectin as a marker of bowel inflammation |
| 1592 - Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency |
| 1591 - Review of immunoglobulin use for secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haemopoietic stem cell transplant |
| 1590 - Review of immunoglobulin use for multifocal motor neuropathy |
| Sixth Community Pharmacy Agreement (6CPA) Pharmacy Practice Incentives (PPI) Programs |
| 1593 - Bovine bioinductive collagen implant for repair of rotator cuff tear |
| 1577 - Autologous fat grafting (AFG) by injection, for treatment of burn scars, and treatment of facial defects due to craniofacial abnormalities |
| 1578 - Arthroscopic injection of a bioadhesive hydrogel implant (JointRep™), in conjunction with microfracture, for treatment of osteochondral defects of the knee |
| 1573 - Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis |
| 1589 – Prognostic value of the number of copies of the survival of motor neurone 2 (SMN2) gene for the severity of spinal muscular atrophy to determine eligibility for nusinersen in pre-symptomatic patients (Co-dependent) |
| 1519.1 - Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma |
| 1435.1 - Processing and Cryopreservation of Ovarian Tissue |
| 1342.5 -
Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission) |
| 1196.2 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (Resubmission) |
| 1510.1 - Emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with Haemophilia A |
| 1192.3 - Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (Resubmission) |
| 1587 - YESCARTA™ (axicabtagene ciloleucel [KTE-C19]) for the treatment of refractory or relapsed CD19-positive lymphoma |
| 1532 - Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325 |
| 1531 - Genetic testing of alpha thalassaemia |
| 1579 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate to severe Haemophilia A (congenital Factor VIII deficiency) WITHOUT Factor VIII inhibitors |
| 1567 - Digital breast tomosynthesis |
| 1560 - 17p Deletion Testing by FISH for Access to Ibrutinib in Patients with Previously Untreated Chronic Lymphoid Leukaemia or Small Lymphocytic Lymphoma |
| 1543 - Request to amend Medicare Benefits Schedule (MBS) item 73336 (BRAF mutation test for treatment of metastatic melanoma) to include reference to encorafenib |
| 1570 - PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) |
| 1574 – Non-Invasive Prenatal Testing (NIPT) for fetal Rhesus D genotype |
| 1569 - Chitosan-based cartilage biomatrix implant (BST-CarGel), in conjunction with the marrow stimulation technique (microfracture), for repair of focal cartilage defects |
| 1575 - Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, cancer treatment/prevention or congenital deformity |
| 1431.1 - HbA1c point of care test for the management of diabetes mellitus |
| 1572 - Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ≥ 140/90mmHg and ≤ 180/110mmHg |
| 1559 - Endoscopic Mucosal Resection |
| Please Note: Information will be published for this application when it becomes available |
| 1564 – Review of immunoglobulin use for Chronic Inflammatory Demyelinating Polyneuropathy |
| 1566 - Review of immunoglobulin use for Myasthenia Gravis |
| 1565 - Review of immumnoglobulin use for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation |
| 1580 - Cardiac ablation for atrial fibrillation |
| 1387.2 - Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure (resubmission) |
| 1405.1 - MBS Item for Pulmonary Rehabilitation (Re-submission) |
| 1544 - Genome-wide microarray testing for people with multiple myeloma and chronic lymphocytic leukaemia |
| 1533 - Genome-wide microarray testing for pregnancies with major foetal structual abnormalities detected by ultrasound |
| 1556 - Human tissue (topical) wound treatments – Ulcers and burns (EpiFix and EpiBurn) |
| 1557 - Human tissue (surgical) wound treatments – Laminectomy and tendon repair (AmnioFix, AmnioWrap and AmnioFix Injectable) |
| 1555 - Endoscopic Sleeve Gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments |
| 1562 – Streamlining Medicare Benefits Schedule Items for Positron Emission Tomography (PET) Project
|
| 1541- Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma (OAG) |
| 1554 - Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy). |
| 1552 - Transcatheter Aortic Valve Implantation (TAVI) via Transfemoral Delivery for Patients at Intermediate Risk for Surgery |
| 1551 - Aspiration therapy via the insertion of a customised percutaneous endoscopic gastrostomy tube into the stomach for weight loss management in obese patients with a BMI ≥ 35 |
| 1546 - Abdominoplasty with repair of rectus diastasis (aka rectus divarication) following pregnancy |
| 1486 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC) |
| 1553 - Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors |
| 1542 - Endovascular insertion of flow diversion device (FDD) for the treatment of unruptured intracranial aneurysms (UIAs) |
| 1534 - Heritable mutations associated with familial hypercholesterolaemia - Clinical Utility Card application |
| 1446 - Hepascore test to diagnose and monitor liver fibrosis severity in chronic liver disease |
| 1515 - Endoscopic placement and removal of an intra-gastric balloon (IGB) for the management of overweight and obesity in a high-risk patient |
| 1441 - Inclusion of eye movement de-sensitisation and reprocessing (EMDR) therapy as a separate Focussed Psychological Therapy under Medicare's Better Access to Psychology Scheme |
| 1538 - Tumour testing to detect somatic BRCA1 or BRCA2 gene mutations, in patients with platinum-sensitive, relapsed high-grade serous ovarian cancer (HGSOC), to determine eligibility for PBS olaparib |
| 1540 - Vigilance testing for the assessment of excessive daytime sleepiness |
| 1523 - Transluminal insertion, management, repositioning and removal of an intravascular microaxial blood pump (Impella®), for patients requiring mechanical circulatory support |
| 1516 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib |
| 1492 – Non-invasive prenatal testing (NIPT) |
| 1504 - Heritable mutations which increase risk in colorectal and endometrial cancer |
| 1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD) |
| 1522 - PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (co-dependent) |
| 1524 - Expanding the BRAF testing MBS item to include patients with resectable Stage III melanoma (co-dependent) |
| 1518 - Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH) |
| 1520 - PD-L1 (Programmed Death 1 Ligand) immunohistochemistry testing for access to pembrolizumab as second/third-line treatment of patients with recurrent or metastatic, unresectable (advanced) adenocarcinoma of the stomach or GEJ (gastro-oesophageal junction) |
| 1440.1 - PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer |
| 1527 - Somatic tumour gene testing for the diagnosis of gliomas, gliobastomas, and soft tissue and bone tumours |
| 1528 - Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast |
| 1512 - Apolipoprotein B testing for high risk cardiovascular disease risk assessment |
| 1526 - Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes |
| 1525 - Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer |
| 1495 - Somatic tumour gene panel test |
| 1180r - Review of items for surgical treatment of obesity |
| 1519 - Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma |
| 1479r - Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369 |
| 1357.1 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer |
| 1482 - New item numbers and rebates for mobile radiology services |
| 1505 - Programmed cell death ligand 1 (PD L1) testing in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) to determine eligibility for durvalumab monotherapy or durvalumab/tremelimumab combination therapy (co dependent). |
| 1511 - Extended half-life (EHL) blood clotting factors VIII + IX |
| 1498 - Serum soluble transferrin receptor |
| 1506 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer |
| 1510 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with Factor VIII inhibitors. |
| 1508 - Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Solid tumours other than colorectal cancer |
| 1507 - Germline BRCA mutation testing to determine eligibility for olaparib treatment in patients with locally advanced or metastatic HER2 negative breast cancer (either hormone receptor positive or triple negative) |
| 1509 - Annular Closure using the Barricaid® mesh prosthesis after discectomy |
| 1342.4 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission) |
| 1456 – 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia |
| 1490 - Breast Magnetic Resonance Imaging for Breast Implant Associated Anaplastic Large Cell Lymphoma |
| 1491 – Vagus nerve stimulation for chronic major depressive episodes |
| 1216.1 - Cystic fibrosis transmembrane regulator (CFTR) testing |
| 1493 - Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma |
| 1472– Cyanoacrylate embolisation for the treatment of varicose veins due to chronic venous insufficiency |
| 1485 – Sentinel Lymph Node Biopsy for intermediate thickness melanoma |
| 1496 Micro-bypass stenting for open-angle glaucoma (external to Schlemm's canal) |
| 1376.1 - 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit |
| 1476 - Genetic testing for childhood syndromes |
| 1464 - Breast Magnetic Resonance Imaging for improved definition of the breast cancer primary |
| 1473 - A 50 gene signature assay for predicting breast cancer recurrence |
| 1468 - SIR-Spheres for the treatment of hepatic metastases, and other indications not listed on the MBS |
| 1483 Micro-bypass stenting for open-angle glaucoma (in trabecular meshwork) |
| 1146.3 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn Disease (Resubmission) |
| 1455 - Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program |
| 1467 - Obstetric MRI |
| 1372.1 MRI for patients with colorectal carcinoma (CRC) with suspected hepatic metastases or patients with suspected hepatocellular carcinoma (HCC) for the purposes of staging |
| 1196.1 - Repetitive Trans cranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission) |
| 1466 - Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration |
| 1475 - Ablative fractional laser resurfacing for burn scar treatment |
| 1460 - Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC) |
| 1454 - Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment |
| 1457 PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy.
|
| 1449 Genetic testing for Alport syndrome |
| 1461 Non-invasive prenatal testing for common trisomies (21, 18 and 13)
|
| 1458 Non-Invasive Prenatal Testing (NIPT) |
| 1453 PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma
|
| 1452 Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma |
| 1398.1 - Implantation of a permanent wireless haemodynamic sensor and associated remote analysis of pulmonary artery pressure for patients with moderate chronic heart failure (New York Heart Association class III) |
| 1362.1 - Resubmission Cetuximab and RAS testing under MBS 73330 |
| 1411.1 - Genetic testing for hereditary mutations predisposing to cancer (breast and/or ovarian) (resubmission) |
| 1151 - Six Genetic tests for the Diagnosis of Inheritable Cardiac Conduction Disorders |
| 1436 - Ovarian Repositioning |
| 1165.1 - Pre-implantation genetic diagnosis (PGD) assessment |
| 1406 - 18F-FDG PET for indolent non-Hodgkin’s lymphoma |
| 1347.1 - Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation (resubmission) |
| 1358.1 - Vagus Nerve Stimulation Therapy (resubmission) |
| 1387.1 - OPTIMIZER TM IVs Implantable Pulse Generator (IPG) – cardiac contractility modulation therapy for patients with heart failure (resubmission) |
| 1435 - Processing and Cryopreservation of Male and Female Gonadal Tissue and Gametes Prior to or after Gonadotoxic Treatment to Preserve Fertility for the Future |
| 1420 - Extracorporeal photopheresis for treatment of acute and chronic graft-versus-host disease and cutaneous T-cell lymphoma |
| 1432 - Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies |
| 1384.1 - Bronchial thermoplasty for the treatment of severe persistent asthma (Resubmission) |
| 1440 - PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer |
| 1445 - PD-L1 testing for access to pembrolizumab in patients with recurrent or progressive metastatic bladder cancer that has recurred or progressed following platinum-based chemotherapy |
| 1431 - HbA1c point of care test for the diagnosis and management of diabetes mellitus |
| 1443 - Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke |
| 1439 - Intravesical instillation of sodium hyaluronate (1.6%) & sodium chondroitin sulphate (2.0%) for Painful Bladder Syndrome / Interstitial Cystitis, Recurrent Urinary Tract Infection and Radiation Induced Cystitis |
| 1342.3 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission) |
| 1192.2 - Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (Resubmission) |
| 1411 - Genetic testing for hereditary mutations predisposing to cancer (breast and/or ovarian) |
| 1172.1 - Testing for BRAF mutation in patients with metastatic melanoma for access to vemurafenib (resubmission) |
| 1361.2 - Transcatheter Aortic Valve Implantation via Transfemoral or Transapical Delivery (Resubmission) |
| 1422 - Minimally invasive, lumbar decompression and dynamic stabilisation using an interlaminar device, with no rigid fixation to the vertebral pedicles, implantation between the spinous processes of one or two lumbar motion segments |
| 1434 - Anti-Müllerian hormone testing |
| 1429 - Intraoperative Radiotherapy for Early Stage Breast Cancer |
| 1428 - Mechanical thrombectomy |
| 1344.1 - Assessment of foot and ankle services by podiatric surgeons (Resubmission) |
| 1365.1 - Active middle ear implants for sensorineural hearing loss (Resubmission) |
| 1342.2 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission) |
| 1424 - MR guided biopsy procedures for diagnosis of prostate cancer |
| 1414 - PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC |
| 1163.1 - Testing for HER2 status in Gastric Cancer for access to trastuzumab |
| 1331 - Review of archival tissue for further diagnostic testing |
| 1400 - Clinical Neuropsychology Assessment Services |
| 1360.1 - Specialist dermatology services delivered by asynchronous store and forward technology (resubmission) |
| 1408 - A prognostic RT-qPCR test run locally for ER+ve /HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment. |
| 1407 - EGFR mutation testing to determine eligibility for access to PBS subsidised AZD9291 second line therapy in patients with locally advanced or metastatic NSCLC |
| 1405 - MBS Item Number for Pulmonary Rehabilitation |
| 1403 - Lung Microwave Tissue Ablation |
| 1402 - Liver Microwave Tissue Ablation |
| 1397 - mpMRI prostate diagnostic scans |
| 1399 - Percutaneous Tibial Nerve Stimulation administered through the Urgent PC Neuromodulation |
| 1401 - Endobronchial Coil Procedure |
| 1393-Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies |
| 1395 - Fluorescence guided resection of high grade (grade IV) glioma that are glioblastoma multiforme using Gliolan (aminolevulinic acid) |
| 1392 - Corneal Collagen Cross Linking as early intervention in progressive keratoconus |
| 1385 - Shared Medical Appointments (SMAs) for Type 2 Diabetes Management |
| 1398 - Implantation of a permanent leadless and batteryless haemodynamic sensor and associated remote analysis of pulmonary artery pressure for patients with moderate chronic heart failure (New York Heart Association class III). |
| 1366 - Transient Elastography at 50Hz for the diagnosis of Liver Fibrosis in patients with confirmed Hepatitis B or confirmed Hepatitis C |
| 1394 - C1 Esterase Inhibitor |
| 1250.1 - Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission) |
| 1197.1 - Remote Monitoring of Patients with Implanted Cardiac Devices |
| 1396 - Noninvasive prenatal testing for common trisomies (21, 18 and 13) |
| 1390 - Epicutaneous Patch Testing |
| 1369 - Male stress urinary incontinence, sling operation for, with or without synthetic mesh |
| 1384 - Bronchial thermoplasty for the treatment of severe persistent asthma |
| 1387 - Cardiac Contractility Modulation (OPTIMIZER™ IVs) |
| 1386 - Gastric Contractility Modulation (GCM) therapy for patients with Type 2 Diabetes with Obesity (DIAMOND™ system Funding Application) |
| 1391 - Rapid point of care combined Antigen/Antibody HIV test to aid in the diagnosis of HIV infection |
| 1379 - IncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb |
| 1361 and 1361.1 - Transcatheter Aortic Valve Implantation via Transfemoral or Transapical Delivery |
| 1380 - BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer |
| 1356 - Melanoma surveillance photography – total body photography and digital dermoscopy
|
| 1189 - Targeted intraoperative radiotherapy (IORT) for early breast cancer |
| 1377 - Optical coherence tomography (OCT) for retinal assessment in the presence of diabetic macular oedema (DMO) for access to treatment with dexamethasone posterior segment drug delivery system |
| 1342.1 - Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission) |
| 1351 - Point of care tests to exclude pre-term labour:Quantitative Fetal Fibronectin (fFN) testing for predicting pre-term labour |
| 1376 - MammaPrint® 70-gene microarray mRNA gene expression profile breast cancer signature to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit. |
| 1372 - MRI Liver – Scan for the detection and characterisation of focal liver lesions |
| 1192.1 - The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques (resubmission) |
| 1234 - Pathology tests for active mycobacterial infection |
| 1367 - Gastrointestinal liner ['EndoBarrier'] to treat diabetes and obesity |
| 1365 - Active middle ear implants for sensorineural hearing loss |
| 1364 - Active middle ear implant for mixed and conductive hearing loss |
| 1345 - Cone Beam CT for dental/craniofacial imaging |
| 1158.1 - Robotic Image-guided stereotactic precise beam radiosurgery and radiotherapy for lung (Cyberknife) - resubmission |
| 1354 - Intravascular ultrasound (IVUS) guided coronary stent insertion |
| 1374 - Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD) |
| 1370 - Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole |
| 1363 - RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients |
| 1362 - Cetuximab and KRAS testing under MBS 73330 |
| 1358 - Vagus Nerve Stimulation Therapy |
| 1335 - Point of Care Tests to exclude preterm labour: Phosphorylated Insulin-like Growth Factor Binding Protein test |
| 1216 - Cystic fibrosis transmembrane regulator (CFTR) testing |
| 1355 - Review of Medicare funded finger fracture services |
| 1237 - Cardiovascular MRI |
| 1359 - Perioperative Nurse Surgical Assistants (PNSA) to gain eligibility as providers of services that attract a Medicare Benefit Schedule (MBS) rebate for eligible surgical assisting services provided during surgery or procedures. |
| 1350 - Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) |
| 1346 - Amendment to MBS Item 11820 |
| 1348 - Transcatheter closure of ventricular septal defect |
| 1357 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer |
| 1360 - Specialist dermatology services delivered by asynchronous store and forward technology |
| 1169 - Sports and Exercise medicine consultation Items |
| 1338 - Catheter-based renal denervation for treatment-resistant hypertension |
| 1353 - Measurement of Calprotectin as a marker of bowel inflammation |
| 1165 - Pre-implantation genetic diagnosis (PGD) assessment |
| 1347 - Transcatheter occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation |
| 1318 - KRAS mutation testing for access to panitumumab |
| 1205a - Review of Medicare–funded Wrist Surgery services |
| 1344 - Assessment of foot and ankle services by podiatric surgeons |
| 1146.1 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn Disease (Resubmission) |
| 1333 - Breast Magnetic Resonance Imaging (MRI) |
| 1332 - Second Opinion for Morphological/Interpretive Pathology |
| 1309 - Pain Medicine Professional Attendance Items |
| 1308 - Local anaesthetic (LA) nerve blockade for post-surgical analgesia |
| 1233 - Out of hours emergency coronary angiography and/or coronary angioplasty and stenting |
| 1181 - Non-mydriatic retinal photography (NMP) in persons with diabetes |
| 1334 - Subcutaneous Immunoglobulins (SCIg) |
| 1342 - Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit |
| 1330 - Transcatheter closure of a patent ductus arteriosus |
| 1319 - The use of Image Guided Radiation Therapy (IGRT) in the treatment of cancer |
| 1293 - Codependent with PBAC- EGFR testing in Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer to determine eligibility for afatinib |
| 1317 - Bone Mineral Density using Dual Energy X-Ray Absorptiometry (DXA) in patients with HIV |
| 1176 - Assessment of application for Joint Injections |
| 1300 - Removal of gynaecomastia from the liposuction component in Barraquers-Simon’s Syndrome (MBS Item 45585) |
| 1299 - Proposed amendment to transperineal ultrasound prostate biopsy (MBS Item 37219) |
| 1230 - Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab |
| 1313 - Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment |
| 1316 - Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) for persons aged 50 - 69 with specific risk factors |
| 1243 - The removal of imbedded corneal foreign bodies to any person presenting to an optometrist. |
| 1191 - Endovascular treatment of intracranial aneurysms-Pipeline Embolization Device (PED) |
| 1263 - Intra-abdominal Vagal Nerve Inhibition for the Management of Obesity |
| 1310 - Optical Coherence Tomography |
| 1269 - Computed Tomography Colonography |
| 1248 - Bone Densitometry to Assess Patient Eligibility to alendronate |
| 1272 - Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder |
| 1162 - Bone Densitometry testing for menopausal women aged 50 |
| 1223 - Insertion, replacement, or removal of a cardiac resynchronisation therapy device capable of defibrillation (CRT-D) for mild, moderate or severe chronic heart failure (NYHA II, III or IV) |
| 1297 - HBA1c test for the diagnosis of diabetes mellitus |
| 1197 - Remote Monitoring of Patients with Implanted Cardiac Devices |
| 1196 - Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression. |
| 1267 - HBA1c Test for the Diagnosis of Diabetes Mellitus |
| 1206 - Single Balloon Enteroscopy System for Obscure GI Bleeding (Small Bowel) |
| 1194 - Single dose stereotactic radiosurgery for benign and malignant intracranial tumours |
| 1183 - Ultrasound imaging in the practice of anaesthesia. |
| 1182 - The use of Intensity Modulated Radiation Therapy (IMRT) |
| 1159 - Palliative Care consultation Items |
| 1203 - Catheter-free ambulatory pH test for gastroesophageal reflux disease (GORD) |
| 1170 - Intensive Care Medicine consultation Items |
| 1171 - Sexual Health Medicine consultation Items |
| 1167 - Addiction medicine consultation Items |
| 1195 - F-18 Flurodeoxyglucose Positron Emission Tomography (FDG PET) for the diagnosis of Alzheimer's Disease |
| 1268 - Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases |
| 1250 - Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib |
| 1273 - Matrix-induced Autologous Chondrocyte Implant |
| 1222 - A genetic test to establish the diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP) for access to tafamidis meglumine |
| 1211 - Volumetric Modulated Arc Therapy for Lung, Prostate, breast and other extracranial cancers such as spine, kidney, liver and pancreatic. |
| 1276 - National Cervical Screening Program renewal |
| 1190 - MRI for small bowel and pelvis in Crohn disease |
| 1242 - yttrium-90 microsphere radioembolisation to embolise the microvasculature of hepatic primary and secondary cancers |
| 1175 - Testing for HER-2 status in Advanced or Metastatic Breast Cancer (stage IIIA-IV) to Access lapatinib |
| 1192 - Percutaneous Reconstruction of an Insufficient Mitral Valve through Tissue Approximation using Transvenous/ Transeptal Techniques |
| 1221 - Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity |
| 1207 - Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies |
| 1178r2 - Review of MBS items for specific ophthalmology services under the MBS Quality Framework Stage II |
| 1152 - Genetic testing for hereditary mutations in the RET gene |
| 1168 - Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine |
| 1172 - Testing for BRAF mutation in patients with advanced melanoma for access to vemurafenib |
| 1166 - Radiofrequency ablation (RFA) for the treatment of varicose veins due to chronic venous insufficiency |
| 1174 - Pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc |
| 1173 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib |
| 1158 - Robotic image-guided stereotactic precise beam radiosurgery and radiotherapy |
| 1098.1 - Review of Interim Funded Service: Breast MRI |
| 1161 - Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer |
| 1157 - Cell enrichment liquid based cytology in routine screening for the prevention of cervical cancer |
| 1163 - Testing for gastric cancer for access to trastuzumab |
| 1160 - Hepatitis C testing for access to Telaprevir |
| 1154 - Patient Monitor Module for non-invasive assessment of artificial stiffness and titration of anti-hypertensive medication in Chronic Kidney Disease |
| 1156 - Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer |
| 1153 - Genetic Testing for Hereditary Mutation of the von Hippel-Lindau (VHL) Gene |
| 1150 - Insertion of Colonic Stents |
| 1149 - Holmium Laser Enucleation of the Prostate (HOLEP) Combined with Tissue Morcellation |
| 1145 - Artificial Intervertebral Disc Replacement in Patients with Cervical Degenerative Disc Disease |
| 1147 - Implantation of fiducial markers into the prostate gland or prostate surgical bed for external beam radiotherapy |
| 1146 - Capsule Endoscopy for the Diagnosis of Suspected Small Bowel Crohn's Disease |
| 1054.1 - Review of Interim Funded Service: Hyperbaric Oxygen Treatment (HBOT) |
| 1143 - Radiofrequency Ablation in Barrett's Oesophagus with Dysplasia |
| 1144 - Pathology Tests for Latent Mycobacterial Infection |
| 1089.1 - Review of Interim Funded Service: Brachytherapy for the Treatment of Prostate Cancer |
| 1090.1 - Review of Interim Funded Service: Artificial Intervertebral Disc Replacement - Lumbar |
| 1140 - Matrix-induced Autologous Chondrocyte Implantation (MACI) and Autologous Chondrocyte Implantation (ACI) |
| 1134 - The Injection of Poly-L-lactic Acid (Sculptra) for the Treatment of Facial Lipoatrophy Caused by Antiretroviral Therapy in HIV Positive Patients |
| 1139 - Measurement and Determination of Procalcitonin (PCT) |
| 1137 - Middle Ear Implant for Sensorineural, Conductive and Mixed Hearing Losses |
| 1110 - MRI for staging of rectal carcinoma |
| 1130 - Unattended Sleep Studies in the Diagnosis of Obstructive Sleep Apnoea |
| 1129 - Second Generation Contrast Agents for Use in Patients with Suboptimal Echocardiograms |
| 1131 - Assessment of Liver Iron by R2-MRI data analysis |
| 1125 - Molecular Testing for the Diagnosis of Myeloproliferative Disorders |
| 1126 - Molecular Testing for Developmental Delay/Mental Retardation |
| 1119 - Capsule Endoscopy for Peutz - Jeghers Syndrome |
| 1127 - Genotypic Resistance Testing of Antiretrovirals in HIV |
| 1124 - Cryotherapy for Recurrent Prostate Cancer and Renal Cancer |
| 1123 - Computer-Navigated Total Knee Arthroplasty (CATKA) |
| 1122 - Automation-Assisted and Liquid-Based Cytology (LBC) for Cervical Cancer Screening |
| 1118 - Vagus nerve stimulation |
| 1116 - Macular Optical Coherence Tomography |
| 1117 - Real-time measurement of cardiac output and other cardiac flow parameters (without concurrent cardiac imaging) using continuous wave Doppler techniques |
| 1111 - Remote Monitoring Systems for Patients with Implanted Cardiac Device |
| 1114 - Urinary metabolic profile |
| 1109 - Deep brain stimulation for essential tremor and dystonia |
| 1113 - Endovenous Laser Therapy for varicose veins (ELT) |
| 1112 - Intragastric Balloon |
| 1108 - Endobronchial ultrasound +/- fine needle aspiration in lung cancer staging and the diagnosis of mediastinal masses |
| 1107 - Acticon artificial bowel sphincter |
| 1024 - Total ear reconstruction |
| 1046 - Sacral nerve stimulation implant (SNSI) for refractory lower urinary tract dysfunction of the following types: urge incontinence, urgency-frequency and retention/overflow |
| 1089 - Brachytherapy for the treatment of prostate cancer |
| 1076 - High-energy transurethral microwave thermotherapy for benign prostatic hyperplasia |
| 1056 - Leukoscan®: For use in diagnostic imaging of the long bones and feet in patients with suspected osteomyelitis, including those with diabetic foot ulcers |
| 1054 - Hyperbaric oxygen therapy for the treatment of non-healing, refractory wounds in non-diabetic patients and refractory soft tissue radiation injuries |
| 1053 - Placement of artificial bowel sphincters in the management of faecal incontinence |
| 1062 - CEA-Scan® for imaging of recurrence &/or metastases in patients with histologically demonstrated carcinoma of the colon or rectum |
| 1049 - M-VAX™ - a treatment for patients with advanced Stage III melanoma |
| 1045 - Intra-articular viscosupplementation for treatment of osteoarthritis of the knee |
| 1044 - Ostase immunoassay for the mass measurement of serum bone alkaline phosphatase |
| 1048 - Intradiscal electrothermal anuloplasty: A treatment for patients with chronic low back pain due to anular disruption of contained herniated discs |
| 1047 - Endoluminal gastroplication for gastro-oesophageal reflux disease |
| 1014 - Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia |
| 1041 - Intravascular Brachytherapy for Coronary Artery Restenoses |
| 1015 - Directional vacuum-assisted breast biopsy |
| 1043 - Recombinant human thyroid stimulation hormone (rhTSH) diagnostic agent for use in well-differentiated thryoid cancer |
| 1039 - Photodynamic therapy with Verteporfin for macular degeneration |
| 1036 - Percutaneous transluminal coronary rotational atherectomy for lesions of the coronary arteries |
| 1038 - Conformal radiotherapy |
| 1037 - Advanced breast biopsy instrumentation (ABBI®) system for non-palpable breast lesions |
| 1035 - Genetic test for Fragile X syndrome |
| 1031 - Deep brain stimulation for the symptoms of Parkinson's disease |
| 1029 - Brachytherapy for the treatment of prostate cancer |
| 1026 - Evaluation of near patient cholesterol testing using the Cholestech LDX |
| 1021 - Hepatitis C viral load testing |
| 1018 - 1020 - Hyperbaric oxygen therapy (HBOT) |
| 1016 - Samarium153-lexidronam for pain due to skeletal metastases |
| 1034 - Selective internal radiation therapy (SIRT) for hepatic metastases using SIR-Spheres® |
| 1032 - Intravascular ultrasound |
| 1028 - Gamma knife radiosurgery |
| 1030 - Low intensity ultrasound treatment for acceleration of bone fracture healing - Exogen™ bone growth stimulator |
| 1023 - Placement of artificial bowel sphincters in the management of faecal incontinence |
| 1106 - Endoscopic argon plasma coagulation therapy |
| 1010 - Intravascular extraction of chronically implanted permanent transvenous pacing leads |
| 1007 - Saline infusion sonohysterography |
| 1005 - Visual electrodiagnosis |
| 1003 - OctreoScan® scintigraphy for gastroentero-pancreatic neuroendocrine tumours |
| 1002 - Oto-acoustic emission audiometry |
| 1012 - Vertebral axial decompression therapy for chronic low back pain |
| 1011 - Lung volume reduction surgery |
| 1008 - Photodynamic therapy for skin and mucosal cancer |
| 1006 - Endoluminal grafting for abdominal aortic aneurysm |
| 1004 - Transmyocardial laser revascularisation (TMR) |
| 1001 - Advanced breast biopsy instrumentation (ABBI) |
| 1009 - Sacral nerve stimulation for refractory urinary urge incontinence or urinary retention |
| 1077 - Sacral nerve stimulation for faecal incontinence |
| 1042 - Cardiac resynchronisation therapy (CRT) |
| 1071 - The use of INR point-of-care testing in general practice |
| 1068 - Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer |
| 1115 - Sacral Nerve Stimulation for Urinary Indications |
| 1055 - Hysteroscopic Sterilisation by Tubal Canulation and Placement of Intrafallopian Implant |
| 1050 - Optical Biometry using partial coherence interferometry prior to cataract surgery |
| 1059 - Endo Venous Laser Treatment for Varicose Veins |
| 1057 - M2A® Capsule Endoscopy: For the evaluation of obscure gastronintestinal bleeding in adult patients |
| 1052 - Radiofrequency ablation of liver tumours |
| 1102 - Double Balloon Enteroscopy |
| 1105 - Computed Tomography Coronary Angiogram - Multi-slice computed tomography coronary angiography in the visualisation of coronary arteries |
| 1104 - Endoscopic ultrasound and fine needle aspiration for lung cancer |
| 1103 - Fetal Fibronectin test for Preterm Labour |
| 1082 - SIR-Spheres ® for the treatment of non-resectable liver tumours |
| 1083 - Intac Implants |
| 1101 - Repetitive Transcranial Magnetic Stimulation (rTMS) |
| 1100 - Intersphinteric Injection of Silicone Biomaterial for Severe Passive Faecal Incontinence |
| 1099 - Lumbar Non-fusion Posterior Stabilisation Devices |
| 1098 - Breast magnetic resonance imaging (MRI) |
| 1096 - Hepatitis B DNA testing |
| 1095 - Computed tomography colonography |
| 1093 - Endovascular Neurointerventional Procedures |
| 1092 - Deep brain stimulation for the symptoms of Parkinson's disease |
| 1091 - Laparoscopic remotely assisted radical prostatectomy |
| 1084 - Uro Vysion Fluorescence Insitu Hybridization (FISH) Assay |
| 1078 - Multifocal multi-channel objective perimetry for the diagnosis of visual field defects |
| 1067 - Genotypic resistance testing of antiretrovirals in HIV |
| 1090 - Artificial Intervertebral Disc Replacement (AIDR) |
| 1061 - Implantable Loop Recorder for Unexplained Syncope - Reveal Plus® |
| 1072 - Endoscopic ultrasound for staging pancreatic, gastric, oesophageal and hepato-biliary neoplasms |
| 1065 - Sentinel lymph node biopsy |
| 1063 - Photodynamic therapy for Verteporfin (Visudyne) for Subfoveal choroidal neovascularisations (Commercial in Confidence) |
| 1060 - Bone Mineral Densitometry |
| 1033 - Autologous chondrocyte implantation (ACI) |
| 1085 - Carbon Labelled Urea Breath Test |
| 1081 - Uterine Artery Embolisation (UAE) 1 |
| 1080 - Coronary (Radi) pressure wire |
| 1079 - Peripheral Arterial Tonometry with Ascending Aortic Waveform Analysis using the SphygmoCor System |
| 1086 - Measurement of B-Type Natriuretic Peptide |
| 1087 - Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure |
